
Tirucap 200 mg (Capivasertib)
200mg
Tablet · Prescription medication
AstraZeneca Korea Co., Ltd.
Capivasertib is an antineoplastic ingredient used in the treatment of malignant tumors.
MFDS ingredient code M284518
Capivasertib is classified as an antineoplastic agent, used to inhibit the growth and survival of cancer cells. It mainly functions by blocking specific signaling pathways to prevent the proliferation of cancer cells.
Capivasertib inhibits specific protein kinases within cancer cells, blocking cell growth signals. This leads to the induction of apoptosis in cancer cells, preventing their proliferation.
Approved uses differ by product. Check each product's information for its actual use.
Unlike other chemotherapeutic agents, Capivasertib selectively targets specific signaling pathways, which is characterized by its ability to suppress cancer cells effectively while reducing side effects.
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, dosage and approved uses can differ by strength, dosage form and combined ingredients. Check each product's information before taking it.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
Product approval information is based on drug information provided by the Ministry of Food and Drug Safety.
Ingredient and class descriptions are not part of MFDS data and were written separately by Cashdoc.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.